Drugs / Citicoline
Citicoline
also known as
CDP-Choline · cytidine-5'-diphosphocholine · Cdp-cholin · CDP-choline 5'-diphosphocholine · Cebrolux · Cebrolux -CIT · Cebrolux-Tubilux · Cebroton · +14 more
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01582113 | Jun 2012 → May 2017 | — | Deborah Yurgelun-Todd | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06522581 | Jan 2024 → Jan 2025 overdue | brain hypoxia - ischemia | Armed Forces Hospital, Pakistan | Recruiting | No outcome recorded |
| Phase 1 | NCT02823106 | Aug → Sep 2016 | ischemic stroke | Justin Fraser | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05881135 | Jun 2023 → Mar 2025 overdue | COVID-19 | Ohio State University | Active not recruiting | No outcome recorded |
| Phase 28 trials · 1 missed | ||||||
| Phase 2 | NCT07804498 | Jun 2026 → Dec 2027 expected | delirium | University of Milano Bicocca | Recruiting | No outcome recorded |
| Phase 2 | NCT05870111 | Oct 2024 → Apr 2026 overdue | alcohol-related disorders | Medical University of South Carolina | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02630069 | Mar 2015 → Dec 2022 | substance-related disorder | Ewha Womans University Mokdong Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02197104 | Jan 2015 → Jan 2017 | fragile X-associated tremor/ataxia syndrome | Rush University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01591759 | Apr 2012 → Apr 2014 | traumatic brain injury | Mclean Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00158249 | Sep 2009 → Jan 2013 | cannabis dependence | Mclean Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00727246 | Mar 2009 → May 2013 | brain injury | Patricia M. Arenth | Completed | Missed primary |
| Phase 2 | NCT00509067 | Nov 2007 → Mar 2011 | schizophrenia | Georgetown University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04802785 | Jun → Jul 2021 | — | Dinara Zhumanbayeva | Unknown | No outcome recorded |
| Phase 38 trials · 2 missed | ||||||
| Phase 3 | NCT06431113 | Jan 2024 → Mar 2025 | glaucoma | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Phase 3 | NCT05710198 | Dec 2023 → Apr 2026 overdue | open-angle glaucoma | Omikron Italia S.r.l. | Recruiting | No outcome recorded |
| Phase 3 | NCT03966170 | May 2019 → Nov 2028 expected | — | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT03949049 | Feb 2019 → Dec 2029 expected | perinatal asphyxia | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT03181646 | Jun → Dec 2017 | brain hypoxia - ischemia | Armed Forces Hospital, Pakistan | Unknown | No outcome recorded |
| Phase 3 | NCT00950352 | Jan 2010 → Dec 2012 | methamphetamine dependence | Perry Renshaw | Completed | No outcome recorded |
| Phase 3 | NCT00545662 | Jul 2007 → May 2011 | traumatic brain injury | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Terminated | Missed primary |
| Phase 3 | NCT00331890 | Oct 2006 → Feb 2012 | cerebral infarction | Ferrer Internacional S.A. | Terminated | Missed primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT03046693 | Jan → Apr 2017 | non-arteritic anterior ischemic optic neuropathy | Valen Chia | Completed | No outcome recorded |
| Phase 4 | NCT02840591 | Jul 2016 → Nov 2017 | delirium | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00404729 | Feb 2005 → Feb 2006 | glaucoma, optic nerve disorder, visual pathway disorder | Fondazione G.B. Bietti, IRCCS | Completed | No outcome recorded |
| Phase not applicable4 trials · 1 met primary | ||||||
| — | NCT04003090 | Mar 2018 → Jan 2019 | neurodegenerative disease | Istituto di Ricerca Neuroftalmologia S.r.l. | Completed | No outcome recorded |
| — | NCT01515917 | Nov 2013 → Jul 2016 | substance abuse, substance dependence, traumatic brain injury | Deborah Yurgelun-Todd | Withdrawn | No outcome recorded |
| — | NCT01502813 | Feb 2012 → Oct 2018 | — | Deborah Yurgelun-Todd | Completed | No outcome recorded |
| — | NCT00377299 | Oct 2006 → May 2009 | amphetamine abuse, bipolar disorder, drug dependence, major depressive disorder | University of Texas Southwestern Medical Center | Completed | Met primary |
| Comparator or background therapy7 trials | ||||||
| Phase 3 | NCT06210646 Comparator | Dec 2022 → Jun 2024 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05154903 Comparator | Jul 2021 → Apr 2022 | ischemic stroke | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT01388738 Comparator | Jan → Oct 2011 | stroke disorder | Clinical Institute of the Brain, Russia | Completed | No outcome recorded |
| Phase 3 | NCT00223236 Comparator | Jul 2010 → May 2012 | cocaine abuse, cocaine dependence, manic bipolar affective disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02248233 Background | Oct 2014 → Sep 2015 | cerebral infarction | Fengtian Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02074735 Comparator | Apr 2014 → Oct 2016 | alcohol dependence | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00619723 Comparator | Apr 2008 → Apr 2012 | bipolar I disorder, cocaine dependence | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Citicoline | “Ten participants with diagnosed FXTAS were administered 1000 mg of citicoline once daily for 12 months.” NCT02197104 ↗ |
| Known as | Cdp-cholin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | CDP-Choline | “Citicoline, also known as CDP-choline, is a nootropic agent currently used in the treatment of glaucoma” PMID 41599168 ↗ Jan 20264“Cytidine-5-diphosphocholine (CDP-Choline or citicoline)” NCT00404729 ↗ |
| Known as | CDP-choline 5'-diphosphocholine | “Citidine diphosphocoline (CDP-choline 5'-diphosphocholine or Citicoline) is a therapeutic option NAION.” NCT03046693 ↗ |
| Known as | Cebrolux | “were treated with Citicoline (oral treatment:1600 mg/die per 60 days) (Cebrolux®, Tubilux, Italy)” NCT00404729 ↗ |
| Known as | Cebrolux -CIT | “compared to citicoline 800 mg alone (Cebrolux® - CIT)” NCT06431113 ↗ |
| Known as | Cebrolux-Tubilux | “Citicoline (Cebrolux-Tubilux, Italy, 1600 mg/diem for 60 days” PMID 18325025 ↗ Mar 2008 |
| Known as | Cebroton | “oral (1600 mg/die, Cebrolux, Tubilux Pharma, Pomezia, Rome, Italy) or intramuscular (1000 mg/die, Cebroton, Tubilux Pharma) cytidine-5'-diphosphocholine (citicoline) treatment” PMID 18929133 ↗ 2008 |
| Known as | Ceraxon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | Citicolina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | Citicoline (Vitaae) | “Citicoline (Vitaae®)” NCT04802785 ↗ |
| Known as | Citicoline Sodium | “Drug: Citicoline Sodium” NCT06522581 ↗ |
| Known as | Citicoline sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | Citidine diphosphocoline | “Citidine diphosphocoline (CDP-choline 5'-diphosphocholine or Citicoline) is a therapeutic option NAION.” NCT03046693 ↗ |
| Known as | cytidine diphosphate-choline | “Citicoline (cytidine diphosphate-choline)” NCT05870111 ↗ |
| Known as | cytidine-5'-diphosphate | “Citicoline (cytidine-5'-diphosphate) is a mononucleotide composed of ribose, cytosine, pyrophosphate, and choline” PMID 21397626 ↗ Mar 2011 |
| Known as | cytidine-5'-diphosphate choline | “This study is a 12-week, randomized, double-blind, placebo-controlled trial of cytidine-5'-diphosphate choline (CDP-choline) in amphetamine-type stimulants-using adolescents.” NCT02630069 ↗ |
| Known as | cytidine-5'-diphosphocholine | “Citicoline is the generic name of the pharmaceutical substance that chemically is cytidine-5'-diphosphocholine (CDP-choline)” PMID 24504829 ↗ Mar 20142“Citicoline, cytidine 5-diphosphocholine, is an exogenous substance” NCT06522581 ↗ “Cytidine-5-diphosphocholine (CDP-Choline or citicoline)” NCT00404729 ↗ |
| Known as | IP 302 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | IP 302 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | Nicholin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | NSC-122002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1231700 ↗ |
| Known as | TRAUSAN | “The aim of this study is to assess whether citicoline (TRAUSAN), a neuroprotective agent involved in membrane phospholipid synthesis and neurotransmission, can prevent or...” NCT07804498 ↗ |
| Modality | Other / unclassified | “Citicoline (cytidine-5'-diphosphate) is a mononucleotide” PMID 21397626 ↗ Mar 2011 |
| Route | Intravenous | “1000 mg every 12 h intravenously during the first 3 days and orally thereafter for a total of 6 weeks” PMID 22691567 ↗ Jun 2012 |
| Route | Oral | “1000 mg every 12 h intravenously during the first 3 days and orally thereafter for a total of 6 weeks” PMID 22691567 ↗ Jun 2012 |